Streetbeat News

Stock Prices

OXM

Oxford Industries (NYSE:OXM) reported Q4 2023 earnings of $1.90 per share, missing the $1.95 estimate, and sales of $404.40M, below the $408.18M estimate. This represents a 16.67% decrease in earnings and a 5.73% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:23 pm

ACNT

Ascent Industries reported a Q4 2023 GAAP EPS of $(0.73) and sales of $41.216M, missing the analyst consensus estimate of $63.500M by 35.09%. This represents a 23.93% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:22 pm

SMTC

Semtech has provided its Q1'FY25 financial guidance, expecting net sales of $200M, +/- $5.0M, closely aligning with the estimated $200.57M. The company also forecasts an adjusted EPS of $0.00, +/- $0.04, which is slightly below the estimated $0.02.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:20 pm

INMB

INmune Bio (NASDAQ:INMB) reported Q4 earnings with an EPS of $-0.47, missing estimates by -7%, and a revenue decrease of $69 thousand from the previous year. The company's past earnings miss was followed by a 4% share price drop.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 8:20 pm

RNAC

Cartesian Therapeutics, Inc. (NASDAQ:RNAC), a biotech company, announced the approval of the conversion of its Series A Convertible Preferred Stock and a 1-for-30 reverse stock split effective after trading hours on April 4, 2024. The conversion will occur on April 8, 2024, and the reverse stock split will see the company's common stock trade on a split-adjusted basis starting April 5, 2024. This will reduce the number of outstanding shares from approximately 165.5 million to about 5.5 million before the conversion, and approximately 23.3 million shares after all conversions.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:16 pm

OTLK

Tang Capital Partners has disclosed a 9.99% passive stake in Outlook Therapeutics, indicating a significant investment in the company.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:16 pm

ED

Consolidated Edison's (NYSE:ED) short interest has increased by 7.06% since the last report, with 6.99 million shares sold short, representing 2.73% of its float. This indicates a bearish market sentiment, although it's below the peer group average of 3.27%. The article suggests that an increase in short interest doesn't necessarily predict a stock price fall.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 8:15 pm

GEHC

GE HealthCare Techs (NYSE:GEHC) has seen a decrease in short interest, with the short percent of float falling 3.73% to 4.13%. This indicates fewer shares are being shorted, suggesting a potential shift in market sentiment towards the stock. The company's short interest is also below its peer group average of 4.20%, hinting at relatively more bullish sentiment among investors compared to its peers.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 8:15 pm

XPON

Expion360 (NASDAQ:XPON) reported Q4 earnings with an EPS of $-0.31, missing estimates by -11.0% and showing a revenue decrease of $591 thousand from the previous year. The company has a history of missing EPS estimates, which previously led to a 3.0% drop in share price.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 8:15 pm

NFLX

Netflix's (NYSE:NFLX) short interest has decreased by 18.45% since the last report, with 8.08 million shares sold short, representing 1.9% of its float. This decrease in short interest could indicate a more bullish sentiment towards NFLX among traders. Compared to its peers, Netflix has a lower short interest percentage of 1.9% against an average of 7.21%, suggesting it is less bearishly viewed than its competitors.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 8:15 pm